Advancing Treatments for Post-Traumatic Stress Disorder
Hybrid Public Meeting: In-Person and Virtual
September 6, 2024 | 1-3:30pm (eastern)
The Reagan-Udall Foundation for the FDA, in support of FDA’s ongoing focus on understanding medical need for PTSD treatment with the goal of facilitating treatment development, convened “Advancing Treatments for Post-Traumatic Stress Disorder,” a public meeting with stakeholder comment.
This hybrid event, with both virtual and in-person attendance options, featured a panel discussion with federal partners to explore efforts to accelerate treatment development for PTSD, including psychedelic drug development. Then we opened the in-person and virtual stage for stakeholder comment, hearing from people with lived PTSD experience, including veterans, family members, and patient advocates; researchers and scientists; and drug developers.
Thirty stakeholders had up to three minutes each to present public comment either virtually or in-person. The Foundation worked to ensure a variety of representative voices were heard.
Funding Disclosure: This activity is one part of a multi-part Foundation project related to substance use disorder. The multi-part project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of an overall award of $1,720,109 of federal funds (100% of the project). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA, HHS, or the U.S. Government. For more information, please visit FDA.gov.